Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.








